Progress in the application of CRISPR/Cas system in the precise detection and treatment of diseases associated with viral infections

Authors

  • Minxue Tang

DOI:

https://doi.org/10.54097/rd5m1c10

Keywords:

CRISPR/Cas system; Gene editing; Virus infection.

Abstract

Various pathogens can cause infectious diseases, which can spread from one person or animal to another or even between humans and other animals. Microorganisms, viruses, and parasites make up the majority of pathogens. The disease can typically be spread through direct contact with infected people, contact with their bodily fluids and feces, their contaminated objects, vertical transmission (mom-to-child transmission), soil transmission, water transmission, food transmission, contact transmission, and oral transmission of feces and bodily fluids. The importance of treating infectious diseases is heightened by the fact that they are difficult to totally eradicate and are disseminated so widely. Now, CRISPR/Cas9 has been applied in the field of detection and treatment of diseases related to viral infection. It has the characteristics of high specificity and low off-target rate, and is an emerging approach for rapid and accurate detection of viral infection and safe and effective treatment of diseases related to viral infection. In recent years, the system has been successfully applied in the detection and treatment of many viruses such as HIV, HBV, HPV and multiple herpes virus, and the development prospect is broad. This review introduced the RNA-targeting CRISPR/Cas system's composition, structure, molecular mechanism, and potential application, focused on the research progress of the CRISPR/Cas system in the detection and treatment of viral infection-related diseases, and summarized and forecasted the development of relevant systems and related research.

Downloads

Download data is not yet available.

References

Weixi Yuan, Yunmei Yu, Chuncai Hu. Research progress of CRISPR/Cas9 technology and its improvement measures[J]. Biotechnology Bulletin. 2017 (4). DOI:10.13560/j.cnki.biotech.bull.1985.2017.04.009.

Qiang Pu, Jia Luo, Linyuan Shen. Research progress and application of CRISPR/Cas9 genome editing technology [J], Chinese Journal of Bioengineering, 2015, 35(11), pp.77-84.

Ying Quan, Xiaojuan Zhang, Hui Zhao, Xiaomin Sun, Xiuqi Ma. Advances in the application of CRISPER/Cas9 system in plant genome site-specific modification and crop genetic breeding, Chinese Agricultural Science Bulletin, 2022,38(26), pp.9-14

MAKAROVA K S, WOLF Y I, ALKHNBASHI O S, et al... An updated evolutionary classification of CRISPR-Cas systems [J]. Nat. Rev. Microbiol., 2015, 13(11): 722-736.

Xiaojie Yu. Radiation role of key gene knockout in mitochondrial metabolism mediated by Crisper-cas9 technology. 1994-2022, China Academic Journal Electronic Publishing House, All rights reserved, DOI: http://www.cnki.net

Arica VanderWal. Pulling the plug on viral infections: CRISPR isn’t just about cutting. Science. 2023, (4). DOI:http://dx.doi.org/10.1126/science.abm1184

Crisper-based virus control method https://wenku.baidu.com/view/fc83ec7113a6f524ccbff121dd36a32d7375c782.html?_wkts_=1690470488994&bdQuery=CRISPER+virus infection

Catherine A. Freije, Cameron Myhrvold, Chloe K. Boehm, Aaron E. Lin, Nicole L. Welch, Amber Carter, Hayden C. Metsky, Cynthia Y. Luo, Omar O. Abudayyeh, Jonathan S. Gootenberg, Nathan L. Yozwiak, Feng Zhang, Pardis C. Sabeti, Programmable Inhibition and Detection of RNA Viruses Using Cas13, Molecular Cell, 2019.

Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, Verdine V, Donghia N, Daringer NM, Freije CA et al: Nucleic Acid Detection with CRISPR-Cas13a/C2c2. SCIENCE 2017, 356, pp. 438-442.

Hongzhao Li, Hao Wang, Rui Yin, Min Le, Yan Li, Research progress of pathogenic nucleic acid detection technology based on CRISPR/Cas system, Journal of Zhejiang University (Agricultural and Life Sciences Edition), DOI:10.3785/j.issn.1008-9209.2022.08.051

The use of CRISPR/Cas9 holds promise for targeted elimination of multiple herpes virus infections, DOI:http://www.chinadhbio.com/Read/Read28_6472.html

Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S, HIV virology and pathogenetic mechanisms of infection: a brief overview[J/OL]. Ann Ist Super Sanita, 2010, vol: 46, no. 1, pp. 5-14. DOI-10.4415/ANN_10_01_02.

Guanqun Xing, Qihang Cao, Weiyi Qi, Ruiqi Song, Fei Li, Zhenjie Zhang, Shaoqiong Liu, Application of CRISPR/Cas system in the treatment of viral infectious diseases, Chinese Journal Of Virology, vol.38, no. pp.1459-1469

Ebina H, Misawa N, Kanemura Y, Koyanagi Y, Harnessing the CRISPR/Cas9 system to disrupt latent, HIV-1 provirus[J/OL], Sci Rep, 2013, 3, pp. 2510. DOI: 10.1038/srep02510.

Liu Z, Chen S, Jin X, Wang Q, Yang K, Li C, Xiao Q, Hou P, Liu S, Wu S, Hou W, Xiong Y, Kong C, Zhao X, Wu L, Li C, Sun G, Guo D, Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV -1 infection[J/OL], Cell Biosci, 2017, 7, pp. 47, DOI: 10.1186/s13578-17-0174-2.

Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M, Zhuang K, Ho W, Hou W, Huang J, Guo D, Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV -1 infection[J/OL], Sci Rep, 2015, 5: 15577, DOI: 10.1038/srep15577.

Wang W, Ye C, Liu J, Zhang D, Kimata J T, Zhou P, CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV -1 infection[J/OL]. PLoS One,2014, 9(12): e115987, DOI: 10.1371/journal.pone.0115987.

Xu L, Wang J, Liu Y, Xie L, Su B, Mou D, Wang L, Liu T, Wang X, Zhang B, Zhao L, Hu L, Ning H, Zhang Y, Deng K, Liu L, Lu X, Zhang T, Xu J, Li C, Wu H, Deng H, Chen H, CRISPR-Edited stem cells in a patient with HIV and acute lymphocytic leukemia[J/OL]. N Engl J Med, 2019, 381(13): pp. 1240-1247, DOI: 10.1056/NEJMoa1817426.

Mancuso P, Chen C, Kaminski R, Gordon J, Liao S, Robinson J A, Smith M D, Liu H, Sariyer I K, Sariyer R, Peterson T A, Donadoni M, Williams J B, Siddiqui S, Bunnell B A, Ling B, MacLean A G, Burdo T H, Khalili K, CRISPR based editing of SIV proviral DNA in ART treated non- human primates [J/OL], Nat Commun, 2020, vol. 11no. 1, pp. 6065, DOI: 10.1038/s41467-020-19821-7

Shih C, Yang C C, Choijilsuren G, Chang CH, Liou AT, Hepatitis B virus[J/OL], Trends Microbiol, 2018, vol. 26, no. 4, pp. 386-387, DOI: 10.1016/j.tim.2018.01.009.

Ward H, Tang L, Poonia B, Kottilil S, Treatment of hepatitis B virus: an update[J/OL], Future Microbiol, 2016, vol. 11, no. 12, pp. 1581-1597, DOI: 10.1016/j.jhep.2017.03.021.

Kostyushev D, Kostyusheva A, Brezgin S, Zarifyan D, Utkina A, Goptar I, Chulanov V, Suppressing the NHEJ pathway by DNA -PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved byCRISPR/Cas9[J/OL], Sci Rep, 2019, vol. 9, no. 1, pp. 1847, DOI: 10.1038/s41598-019-38526-6.

Schiwon M, Ehrke-Schulz E, Oswald A, Bergmann T, Michler T, Protzer U, Ehrhardt A, One -vector system for multiplexed CRISPR/Cas9 against Hepatitis B virus cccDNA utilizing high- capacity adenoviral vectors[J/OL], Mol Ther Nucleic Acids, 2018, vol. 12, pp. 242-253.

Yang Y C, Chen Y H, Kao J H, Ching C, Liu I J, Wang C C, Tsai C H, Wu F Y, Liu C J, Chen P J, Chen D S, Yang H C, Permanent inactivation of HBV genomes by CRISPR/Cas9-mediated non-cleavage base editing[J/OL], Mol Ther Nucleic Acids, 2020, vol. 20, pp. 480-490. DOI: 10.1016/j.omtn.2020.03.005.

Fujii W, Kawasaki K, Sugiura K, Naito K, Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease[J/OL], Nucleic Acids Res, 2013, vol. 41, no. 20, pp. e187, DOI: 10.1093/nar/gkt772.

Zhen S, Hua L, Takahashi Y, Narita S, Liu Y H, Li Y, In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9[J/OL], Biochem Biophys Res Commun, 2014, vol. 450, no. 4, pp. 1422-1426, DOI:10.1016/j.bbrc.2014.07.014.

Yoshiba T, Saga Y, Urabe M, Uchibori R, Matsubara S, Fujiwara H, Mizukami H, CRISPR/Cas9 -mediated cervical cancer treatment targeting human papillomavirus E6[J/OL,Oncol Lett, 2019, vol. 17, no. 2, pp. 2197-2206, DOI: 10.3892/ol.2018.9815.

Liu Y C, Cai Z M, Zhang X J, Reprogrammed CRISPR/Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes[J/OL], Asian J Androl, 2016, vol. 18, no. 3, pp. 475-479, DOI: 10.4103/1008-682X.157399.

Downloads

Published

29-12-2023